Biocon receives approval for Insulin Glargine in Mexico through its partner PiSA Farmaceutica
The combined market for Insulin Glargine in Mexico is estimated to be in excess of $40 million
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon
Biocon recognised for outstanding contribution to public health by WHO – India
Biocon's integrated healthcare initiatives is constantly engaged in improving the quality of life of several thousand communities…
ABLE elects new office bearers
To focus on improved strategies to catapult the industry to new heights The executive council of the Association of Biotechnology…
Kiran Mazumdar-Shaw honoured by Federation University Australia
Appointed as an ambassador of the university for a three-year term
Biotech start ups get govt-backed equity fund
The BIRAC AcE Fund aims to accelerate growth of biotech startups
Biocon posts Rs 779 crore revenue in Q3 FY15
Research services delivers 20 per cent growth
Biocon, Sun Pharma awarded for innovation
Study shows high tech engineering, pharma as front runners of innovation in India
Biocon expands its strategic partnership with CytoSorbents
Biocon will now have the exclusive, region-wide rights to distribute CytoSorb for all critical care applications in the ICU as…